Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anidulafungin alternate-interval pharmacokinetics prophylaxis study in high-risk hematology patients
NL-OMON34306Phase 2Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Dec 2010
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of anidulafungin in invasive mycoses and mycoses (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Pharmacokinetics of anidulafungin q48h or q72h. Started Dec 2010; status: active, not recruiting.
02
Drugs
anidulafungin
03
Conditions
invasive mycosesmycoses
Beyond the preview
Go deeper on NL-OMON34306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34306.